213 related articles for article (PubMed ID: 29163686)
1. Characterization of distinct types of
Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
4. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.
Ghimessy AK; Gellert A; Schlegl E; Hegedus B; Raso E; Barbai T; Timar J; Ostoros G; Megyesfalvi Z; Gieszer B; Moldvay J; Renyi-Vamos F; Lohinai Z; Hoda MA; Klikovits T; Klepetko W; Laszlo V; Dome B
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31600989
[TBL] [Abstract][Full Text] [Related]
5. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
6. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
7. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Li P; Li B; Shi Y; Zhang F; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992
[TBL] [Abstract][Full Text] [Related]
8. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immunotherapy in
Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis.
Gu X; Si J; Guan Y; Xu Y; Shao L; Zhang Y; Xu C; Pan W; Lu Y; Song Z; Wang W
Open Med (Wars); 2023; 18(1):20230653. PubMed ID: 36915627
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by
Ruppert AM; Beau-Faller M; Debieuvre D; Ouafik L; Westeel V; Rouquette I; Mazières J; Bringuier PP; Monnet I; Escande F; Ricordel C; Merlio JP; Janicot H; Lemoine A; Foucher P; Poudenx M; Morin F; Langlais A; Souquet PJ; Barlesi F; Wislez M
JTO Clin Res Rep; 2020 Sep; 1(3):100052. PubMed ID: 34589947
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
Sun Y; Li Z; Jian H; Xia L; Lu S
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
[TBL] [Abstract][Full Text] [Related]
18. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characteristics and the Effect of
Gu G; Yu B; Wan H; Lu S; Zhu X; Zhao Y; Fuxi Y; Liu C
Onco Targets Ther; 2022; 15():1021-1032. PubMed ID: 36172169
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
